Evidence map›Paper›PMID 29221125›Full record

ArticleOncotarget2017

TCTN2: a novel tumor marker with oncogenic properties.

David Cano-Rodriguez, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Elisa De Camilli, Chaojun Song, Boquan Jin, Aurelien Lacombe, Andrea Pierleoni, Mauro Bombaci and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 5 countries.

David Cano-Rodriguez *Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands.
Susanna Campagnoli *Externautics SpA, Siena, Italy.
Alberto GrandiExternautics SpA, Siena, Italy.
Matteo ParriExternautics SpA, Siena, Italy.
Elisa De CamilliDepartment of Pathology, European Institute of Oncology, Milan, Italy.
Chaojun SongDepartment of Immunology, The Fourth Military Medical University, Xi'an, China.
Boquan JinDepartment of Immunology, The Fourth Military Medical University, Xi'an, China.
Aurelien LacombeInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Andrea PierleoniExternautics SpA, Siena, Italy.
Mauro BombaciIstituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
Chiara CordiglieriIstituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
Marcel Hj RuitersDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands.
Giuseppe VialeDepartment of Pathology, European Institute of Oncology, Milan, Italy.
Luigi TerraccianoInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Paolo SarmientosExternautics SpA, Siena, Italy.
Sergio AbrignaniIstituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
Guido GrandiCentre for Integrative Biology - CIBIO, University of Trento, Trento, Italy.
Piero PileriExternautics SpA, Siena, Italy.
Marianne G RotsDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands.
Renata GrifantiniExternautics SpA, Siena, Italy.
Air Force Medical University · CNEuropean Institute of Oncology · ITOspedale Maggiore · ITUniversity Hospital of Basel · CHUniversity of Groningen · NLEuropean Bioinformatics Institute · GBFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituto Nazionale Genetica Molecolare · ITUniversity Medical Center Groningen · NLUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tectonic family member 2 (

Indexed as

biomarkercancerepigenetic editingoncogeneTCTN2

Identifiers

PMID29221125
PMCPMC5707019
OpenAlexW2746915874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.